September 1, 2010Current Pharmaceutical Design
Clinical Management of Arrhythmogenic Right Ventricular Cardiomyopathy: An Update
Key result
ARVC management relies on risk stratification, beta blockers, antiarrhythmic drugs, catheter ablation, and ICDs.
Why the study?
Arrhythmogenic right ventricular cardiomyopathy (ARVC) requires updated clinical management strategies due to its complex presentation and progression involving ventricular arrhythmias and heart failure.
Population
Patients with arrhythmogenic right ventricular cardiomyopathy (ARVC)
Comparison
Various clinical management options including beta blockers, antiarrhythmic drugs, catheter ablation, ICD, and heart failure therapy
Design
Review article
Authors
Discussion
Loading...
Member takes
Implication
Supports ICD role in ARVC sudden-death prevention; leaves open optimal selection and timing pending prospective data.
Structured PICO
P
Population
Patients with Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
I
Intervention
Clinical management including beta blockers, antiarrhythmic drugs, catheter ablation, implantable cardioverter defibrillator (ICD), and heart failure therapy
This review outlines the diagnostic criteria, risk stratification, and therapeutic options for ARVC, emphasizing the ICD as the most effective therapy for preventing sudden cardiac death.
Cite This Study
Migliore et al. (2010) conducted a review in Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC). Clinical management strategies was evaluated. Clinical management of arrhythmogenic right ventricular cardiomyopathy relies on risk stratification and therapies including beta blockers, antiarrhythmic drugs, catheter ablation, and ICDs.